Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_assertion description "[Selective inhibition of PI3K? (p110?) by GS-1101 has emerged as a promising therapy in chronic lymphocytic leukemia and indolent lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_assertion evidence source_evidence_literature NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_assertion SIO_000772 23676220 NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_assertion wasDerivedFrom befree-20140225 NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_assertion wasGeneratedBy ECO_0000203 NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.
- befree-20140225 importedOn "2014-02-25" NP277027.RA2LAnBc47gdD5q7xA6_BjtDCS7J4AQ-E-yjcYHKdgZkw130_provenance.